Layer by layer assembly of core-corona structured solid lipid nanoparticles with β-cyclodextrin polymers

Amasya, Gülin; Bakar‐Ates, Filiz; Wintgens, Véronique

doi:10.1016/j.ijpharm.2020.119994

Cited by 16 publications

(11 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The release of standard (not nanoparticle-loaded) MOX was high in the first two hours, after which it kept dropping by the end of hour 4, at which point 95 % of MOX was released, and no more drug was until hour 24. LNPs slowed down its release thanks to its even dispersion in the lipid matrix and diffusion from it, as previously proposed by other authors ( 42 , 43 ).…”

Section: Resultssupporting

confidence: 78%

“…We believe that the higher antibacterial activity of MOX loaded into SLN1 is related to the smaller size of SLN1 and distinct lipid and surfactant features, as earlier studies suggest that lipid nanoparticles with Tween 80 can generate higher antibacterial activity against E. coli ( 42 ). Furthermore, SLN1 can carry MOX directly to the target within the bacterium and also act as efflux pump inhibitor, that is, inhibit drug clearance from the cell ( 14 , 48 ).…”

Section: Resultsmentioning

confidence: 74%

See 1 more Smart Citation

Evaluation of bacterial uptake, antibacterial efficacy against Escherichia coli, and cytotoxic effects of moxifloxacin-loaded solid lipid nanoparticles

Kiymaci

Topal

Eşi̇m

et al. 2022

Archives of Industrial Hygiene and Toxicology

View full text Add to dashboard Cite

Moxifloxacin (MOX) is an important antibiotic commonly used in the treatment of recurrent Escherichia coli (E. coli) infections. The aim of this study was to investigate its antibacterial efficiency when used with solid lipid nanoparticles (SNLs) and nanostructured lipid carriers (NLCs) as delivery vehicles. For this purpose we designed two SLNs (SLN1 and SLN2) and two NLCs (NLC1 and NLC2) of different characteristics (particle size, size distribution, zeta potential, and encapsulation efficiency) and loaded them with MOX to determine its release, antibacterial activity against E. coli, and their cytotoxicity to the RAW 264.7 monocyte/macrophage-like cell line in vitro. With bacterial uptake of 57.29 %, SLN1 turned out to be significantly more effective than MOX given as standard solution, whereas SLN2, NLC1, and NLC2 formulations with respective bacterial uptakes of 50.74 %, 39.26 %, and 32.79 %, showed similar activity to standard MOX. Cytotoxicity testing did not reveal significant toxicity of nanoparticles, whether MOX-free or MOX-loaded, against RAW 264.7 cells. Our findings may show the way for a development of effective lipid carriers that reduce side effects and increase antibacterial treatment efficacy in view of the growing antibiotic resistance.

show abstract

Section: Resultssupporting

confidence: 78%

Section: Resultsmentioning

confidence: 74%

Evaluation of bacterial uptake, antibacterial efficacy against Escherichia coli, and cytotoxic effects of moxifloxacin-loaded solid lipid nanoparticles

Kiymaci

Topal

Eşi̇m

et al. 2022

Archives of Industrial Hygiene and Toxicology

View full text Add to dashboard Cite

show abstract

“…The cytotoxic effects of CSL and CSL/SBE 7 -β-CD/HDBAC on cell lines were evaluated by an MTS [3-(4,5-dimethylthiazol-2-yl)-5(3-carboxymethoxyphenyl)-2-(4-sulfopheny)-2 H -tetrazolium] assay. 35 The liver cancer SMMC-7721, colon cancer SW480, lung cancer A-549, leukemia HL-60, and breast cancer MCF-7 cells were cultured in DMEM supplemented with 10% fetal bovine serum, and then the cells were seeded in 96-well plates with a density of 3000–15000 cells per well in a total volume of 100 μL. The samples were dissolved and added to well plates at 37 °C for 48 h. Compounds were rescreened at five concentrations: 100 μg mL −1 , 20 μg mL −1 , 4 μg mL −1 , 0.8 μg mL −1 , and 0.16 μg mL −1 .…”

Section: Methodsmentioning

confidence: 99%

β-Cyclodextrin-based supramolecular nanoparticles: pH-sensitive nanocarriers for the sustained release of anti-tumor drugs

Yan²,

Jin

et al. 2022

New J. Chem.

View full text Add to dashboard Cite

show abstract

“…Others are exploring different approaches. An interesting example is the layer-by-layer assembly of p𝛽CyD on solid lipid nanoparticles (SLN) of Compritol 888 ATO described by Amiel et al [157] The negatively charged SLN core was successfully coated with positively charged p𝛽CyD to obtain one layer SLN. Two layers SLN were produced by sequential deposition on the SLN of positively charged p𝛽CyD bearing trimethyl ammonium and negatively charged p𝛽CyD with sulfate groups.…”

Section: Future Perspectivesmentioning

confidence: 99%

Implementation of Water‐Soluble Cyclodextrin‐Based Polymers in Biomedical Applications: How Far Are We?

Agnes

Pancani

Fenyvesi

et al. 2022

Macromolecular Bioscience

View full text Add to dashboard Cite

Cyclodextrin-based polymers can be prepared starting from the naturally occurring monomers following green and low-cost procedures. They can be selectively derivatized pre-or post-polymerization allowing to fine-tune functionalities of ad hoc customized polymers. Preparation nowadays has reached the 100 g scale thanks also to the interest of industries in these extremely versatile compounds. During the last 15 years, these macromolecules have been the object of intense investigations in view of possible biomedical applications as the ultimate goal and large amounts of scientific data are now available. Compared to their monomeric models, already used in the formulation of various therapeutic agents, they display superior behavior in terms of their solubility in water and solubilizing power toward drugs incompatible with biological fluids. Moreover, they allow the combination of more than one type of therapeutic agent in the polymeric system. In this review, a complete state of the art on the knowledge and potentialities of water-soluble cyclodextrin-based polymers as therapeutic agents as well as carrier systems for different types of therapeutics to implement combination therapy is provided. Finally, a perspective on their assets for innovation in disease treatment as well as their limits that still need to be addressed is given. Introduction Cyclodextrins at First SightCyclodextrins (CyDs) are water soluble, biocompatible macrocyclic oligosaccharides, made of 𝛼-d-glucopyranose units joined by 𝛼(1-4) linkages (Figure 1a). [1,2] These natural macrocycles

show abstract

Layer by layer assembly of core-corona structured solid lipid nanoparticles with β-cyclodextrin polymers

Cited by 16 publications

References 28 publications

Evaluation of bacterial uptake, antibacterial efficacy against Escherichia coli, and cytotoxic effects of moxifloxacin-loaded solid lipid nanoparticles

Evaluation of bacterial uptake, antibacterial efficacy against Escherichia coli, and cytotoxic effects of moxifloxacin-loaded solid lipid nanoparticles

β-Cyclodextrin-based supramolecular nanoparticles: pH-sensitive nanocarriers for the sustained release of anti-tumor drugs

Implementation of Water‐Soluble Cyclodextrin‐Based Polymers in Biomedical Applications: How Far Are We?

Contact Info

Product

Resources

About